NewsNews
The Future Medicine Initiative (President: Yoshiki Sawa), a general incorporated foundation that strengthens the hub function for the industrialization and international contribution of "future medicine" including regenerative medicine, concluded a Memorandum of Understanding (MoU) with Johnson & Johnson Japan Group regarding the Smart Healthy Aging Initiative to explore the possibility of collaboration and cooperation in solving health issues and creating innovation in a super-aging society. An announcement ceremony was held at the Japan Health venue.
With the Osaka-Kansai Expo currently underway, and the world's attention focused on Osaka, Kansai and the life sciences industry, we believe that the announcement of this MoU will be of great significance to the global healthcare industry.
Aiming to strengthen its competitiveness in the global market, the Institute for Future Medical Research is promoting strategic alliances with overseas bio clusters and promoting international joint research and collaboration with overseas companies. In addition, within Japan, the Institute is playing an important role in facilitating collaboration in the Keihanshin region (Kyoto, Osaka, and Kobe), which has formed world-class research institutes and industrial clusters and developed as an important base in the bio-life sciences field, and is accelerating the development of regenerative medicine ecosystems and startup ecosystems.
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation helps us build a world where we can prevent, treat and cure complex diseases, make treatments smarter and less invasive, and provide personalized solutions for every patient. Leveraging our expertise in Innovative Medicine and MedTech, we will drive innovation across a broad range of healthcare solutions to drive future breakthroughs and make a real impact on people's health.
"Smart Healthy Aging Initiative (SHAI)" is a program promoted by the Johnson & Johnson Japan Group, which aims to extend healthy lifespan and shorten the so-called "lost decade", the approximately 10-year difference between average lifespan and healthy lifespan. By bringing together the technical capabilities and knowledge of a total healthcare company that handles prescription pharmaceuticals and medtech (medical devices and medical device solutions), we aim to create Japan-made solutions that contribute to extending healthy lifespan through open innovation with industry, government, and academia, and to contribute to improving people's quality of life and realizing a sustainable social security system.
This MoU will explore the possibility of collaboration and cooperation mainly in the areas related to solving health issues and creating innovation in a super-aging society, such as promoting the creation of a healthcare ecosystem that contributes to solving health issues and creating innovation, nurturing innovative human resources, and conducting research and demonstrations to develop data-driven solutions using medical and health data.